Novel Approaches to CMV After HCT: Report from the 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22–25 April 2017

References

• Agrawal S, O'Donoghue S, Gowardman J et al. Intensive care unit experience of hemopoietic stem cell transplant patients. Int. Med. J. 42(7), 748–754 (2012).
   Google Scholar
• Lengliné E, Chevret S, Moreau AS. Changes in intensive care for allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 50(6), 840–845 (2015).
   PubMed Web of Science ®Google Scholar
• De La Camara R. CMV in hematopoietic stem cell transplantation. Mediterr. J. Hematol. Infect. Dis. 8(1), e2016031 (2016).
   PubMedGoogle Scholar
• Ljungman P, Boeckh M, Hirsch HH et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin. Infect. Dis. 64(1), 87–91 (2017).
   PubMed Web of Science ®Google Scholar
• Jain NA, Lu K, Ito S et al. The clinical and financial burden of pre-emptive management of CMV disease after allogeneic stem cell transplantation – implications for preventative treatment approaches. Cytotherapy 16(7), 927–933 (2014).
   PubMed Web of Science ®Google Scholar
• Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol. Oncol. Clin. North Am. 25(1), 151–169 (2011).
   PubMed Web of Science ®Google Scholar
• Boeckh M, Nicholls WG, Papanicolaou G et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges and future strategies. Biol. Blood Marrow Transplant. 9(9), 543–558 (2003).
   PubMed Web of Science ®Google Scholar
• Ganepola S, Gentilini C, Hilbers U et al. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant. 39(5), 293–299 (2007).
   PubMed Web of Science ®Google Scholar
• Chemaly R, Shah D, Winston D et al. The impact of pre- and week 2 and week 4 post-transplant CMV-specific Elispot assay on CMV reactivation in CMV-seropositive allogeneic hematopoietic cell transplant (allo-HCT) recipients. Presented at: 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2017). Vienna, Austria, 22–25 April 2017.
   Google Scholar
• Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113(23), 5711–5719 (2009).
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring W, Xie H et al. CMV viral load and mortality after hematopoietic cell transplantation: a cohort study in the era of pre-emptive therapy. Lancet Haematol. 3(3), e119–e127 (2016).
   PubMed Web of Science ®Google Scholar
• McIntosh M, Hauschild B, Miller V. Human cytomegalovirus and transplantation: drug development and regulatory issues. J. Virus Erad. 2(3), 143–148 (2016).
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Rowley SD et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N. Engl. J. Med. 369(13), 1227–1236 (2013).
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Chemaly RF et al. Brincidofovir for prevention of cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT) in CMV-seropositive patients: a randomized, double-blind, placebo-controlled, parallel-group Phase III trial. Biol. Blood Marrow Transplant. 22(3), S23 (2016).
   PubMed Web of Science ®Google Scholar
• Chimerix Inc. Chimerix announces presentation of detailed results from Phase III SUPPRESS trial at BMT Tandem Meetings. (2016). http://ir.chimerix.com/releasedetail.cfm?releaseid=955952
   Google Scholar
• Winston DJ, Young JH, Pullarkat V et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 111(11), 5403–5410 (2008).
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Papanicolaou GA et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a Phase III, double-blind, placebo-controlled, randomized trial. Lancet Infect. Dis. 11(4), 284–292 (2011).
   PubMed Web of Science ®Google Scholar
• Maertens J, Cordonnier C, Jaksch P et al. Maribavir versus valganciclovir for pre-emptive treatment of cytomegalovirus (CMV) viremia: a randomized, dose-ranging, Phase II study among hematopoietic stem cell transplant (SCT) and solid organ transplant (SOT) recipients. Open Forum Infect. Dis. 3(Suppl. 1), 2287 (2016).
   Google Scholar
• Ljungman P, Marty FM, Chemaly R et al. Letermovir (LET) for prevention of cytomegalovirus (CMV) infection: results from a Phase III randomized, double-blind, placebo (PBO)-controlled trial in adult allogeneic hematopoietic cell transplant (alloHCT) recipients. Presented at: The 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2017). Marseille, France, 26–29 March, 2017.
   Google Scholar
• Chemaly R, Dadwal S, Marty F et al. Safety and tolerability of letermovir prophylaxis of cytomegalovirus (CMV) infection in adult CMV-seropositive recipients of allogeneic hematopoietic cell transplantation. Presented at: 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2017). Vienna, Austria, 22–25 April 2017.
   Google Scholar
• Dole K, Segal FP, Feire A et al. A first-in-human study to assess the safety and pharmacokinetics of monoclonal antibodies against human cytomegalovirus in healthy volunteers. Antimicrob. Agents Chemother. 60(5), 2881–2887 (2016).
   PubMed Web of Science ®Google Scholar
• Ozdemir E, Saliba RM, Champlin RE et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 40(2), 125–136 (2007).
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Labopin M, Beelen D et al. CMV serostatus has still an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Blood 122(19), 3359–3364 (2013).
   PubMed Web of Science ®Google Scholar